Inogen INGN 深 沪
等待开盘 08-25 09:30:00 美东时间
5.525
-0.085
-1.52%
华盛通- 最 高5.66
- 今 开5.62
- 成交量 20.03万股
- 最 低 5.525
- 昨 收 5.61
- 总市值 1.47亿
- 52周最高 9.13
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 5.3401
- 委 比 -46.94%
- 总股本 2653.83万
- 历史最高 287.79
- 量 比 1.10
- 振 幅 2.41%
- 历史最低 4.13
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give...
08-19 18:30
Inogen Lowers FY2026 Sales Guidance from $366.000M-$373.000M to $355.000M-$361.000M vs $369.267M Est
Inogen (NASDAQ:INGN) lowers FY2026 sales outlook from $366.000 million-$373.000 million to $355.000 million-$361.000 million vs $369.267 million estimate.
08-07 04:19
Inogen Sees Q3 Sales $92.400M vs $98.967M Est
Inogen (NASDAQ:INGN) sees Q3 sales of $92.400 million vs $98.967 million analyst estimate.
08-07 04:19
Inogen Q2 Sales $95.084M Miss $95.233M Estimate
Inogen (NASDAQ:INGN) reported quarterly sales of $95.084 million which missed the analyst consensus estimate of $95.233 million by 0.16 percent. This is a 3.04 percent increase over sales of $92.277 million the same period last year.
08-07 04:08
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West, with extensive experience scaling medical technologies, previously led Nalu Medical and Intersect ENT, both acquired by large companies. O’Keefe, a seasoned health system leader, managed over $2 billion in revenue at the University of Chicago Medical Center. Their expertise will support Ceribell’s expansion of its ...
07-29 11:00
电话会总结 ｜ Inogen(INGN)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Inogen业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收8,510万美元，同比增长3.4% - 国际营收3,770万美元，同比增长18% - 美国营收3,470万美元，同比下降5% - 美国租赁营收1,270万美元，同比下降8% **盈利能力：** - 调整后毛利率44.7%，同比提升30个基点 - GAAP净亏损830万美元，去年同期亏损620万美元 - 调整后净亏损400万美元，去年同期亏损290万美元 - 调整后EBITDA为负140万美元，去年同期基本盈亏平衡 **现金状况：
05-08 12:05
Inogen Sees Q126 Sales in line with 1Q25
Inogen (NASDAQ:INGN) Sees Q126 Sales in line with 1Q25
02-25 06:09
Inogen Sees Q1 Sales $366.000M-$373.000M vs $90.800M Est
Inogen (NASDAQ:INGN) sees Q1 sales of $366.000 million-$373.000 million vs $90.800 million analyst estimate.
02-25 05:08
Inogen Q4 Adj. EPS $(0.15) Beats $(0.36) Estimate, Sales $81.721M Miss $85.050M Estimate
Inogen (NASDAQ:INGN) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.36) by 57.98 percent. This is a 37.5 percent increase over losses of $(0.24) per share from the same
02-25 05:08
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
